EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitScoping ReviewOpen Access · CC BY 4.0

Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review

Weeratian Tawanwongsri iD, Pitchaya Jaruvijitrattana, Chime Eden

Life · 06.07.2026 · 16 (7) · 1124

DOI: 10.3390/life16071124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 06.07.2026. Verfasst von Weeratian Tawanwongsri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Omalizumab is an effective treatment for antihistamine-refractory chronic urticaria. However, post-injection urticaria exacerbation and related adverse reactions remain inconsistently reported. This scoping review mapped evidence on clinical presentation, timing, mechanisms, management strategies, rechallenge outcomes, treatment discontinuation, and patient outcomes associated with these reactions.

Methods

The review followed the Joanna Briggs Institute methodology and was registered prospectively in INPLASY (INPLASY202650060). PubMed, Scopus, and the Directory of Open Access Journals were searched from inception to April 2026. Eligible studies included English-language case reports, case series, observational studies, cohort studies, registry or pharmacovigilance studies, postmarketing surveillance studies, and clinical trials reporting urticaria-related or hypersensitivity-type adverse reactions during omalizumab treatment for chronic urticaria. Data were charted descriptively and synthesized narratively.

Results

Seventeen studies published between 2015 and 2026 included 2790 patients with chronic urticaria, 60 of whom experienced urticaria-related adverse reactions, corresponding to a mapped proportion of 2.2%. Clinical phenotypes included transient urticaria exacerbation, urticaria flare or worsening, localized urticarial plaques at the injection area, angioedema, anaphylaxis or anaphylaxis-like reactions, and serum sickness-like reactions. Reactions occurred within minutes to several hours, within 24 h, several days, or up to 1 week after injection or dose escalation. Reactions occurred following the first dose, repeated doses, and dose escalation. Proposed mechanisms included delayed hypersensitivity, possible IgE-mediated delayed-onset anaphylaxis, serum sickness-like reaction, paradoxical worsening, infection-associated flare, excipient-related reactions, and severe underlying CSU exacerbation mimicking anaphylaxis. Management strategies ranged from observation or symptomatic treatment to discontinuation of omalizumab and systemic interventions.

Conclusions

Omalizumab-associated urticaria-related adverse reactions were infrequently reported across the mapped evidence but were clinically heterogeneous. Standardized definitions and detailed case reporting are needed to clarify causality, recurrence risk, rechallenge safety, and long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactionanaphylaxisangioedemachronic spontaneous urticariachronic urticariahypersensitivityomalizumabpost-injection reactionscoping reviewurticaria exacerbation

Autor:innen und Institutionen

  • Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand.
  • Center of Excellence in Data Science for Health Study, Walailak University, Nakhon Si Thammarat 80160, Thailand.
  • Division of Dermatology, Department of Internal Medicine, Chaophya Abhaibhubejhr Hospital, Prachin Buri 25000, Thailand.
  • Department of Dermatology, Jigme Dorji Wangchuck National Referral Hospital (JDWNRH), Thimphu 11001, Bhutan.

ORCID-Profile: Weeratian Tawanwongsri

Zitieren

APA

Tawanwongsri, W., Jaruvijitrattana, P., & Eden, C. (2026). Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review. Life, 16(7), 1124. https://doi.org/10.3390/life16071124

Vancouver

Tawanwongsri W, Jaruvijitrattana P, Eden C. Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review. Life. 2026;16(7):1124. doi:10.3390/life16071124

BibTeX
@article{Tawanwongsri2026,
  author = {Tawanwongsri, Weeratian and Jaruvijitrattana, Pitchaya and Eden, Chime},
  title = {Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {1124},
  doi = {10.3390/life16071124}
}
Kostenlos starten →